Tags : Tesaro

Top 20 Biopharma Acquisitions of 2018 Based on the Total

Biopharma acquisition activity in 2018 shows a significant increase over the previous year. Takeda proved to be on top with the acquisition of Shire among the top 20 acquisitions with a total deal value of $57.17B strengthening its capabilities in gastroenterology, neuroscience, oncology, rare diseases, and plasma-derived therapies. This article is based on the 2018 […]Read More

GSK to Acquire Tesaro for its Zejula (niraparib) for $5.1B

Shots: GSK to acquire Tesaro, in all stock transaction with its Zejula and preclinical candidates. Tesaro to get $75/share in cash for a premium of 62% with total deal value of $5.1B The focus of acquisition is to build oncology portfolio with Tesaro’s products for targeting multiple cancers including ovarian, lung and prostate cancer. In […]Read More